0001062993-23-012907.txt : 20230605
0001062993-23-012907.hdr.sgml : 20230605
20230605160325
ACCESSION NUMBER: 0001062993-23-012907
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230601
FILED AS OF DATE: 20230605
DATE AS OF CHANGE: 20230605
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Toth Christopher A.
CENTRAL INDEX KEY: 0001753950
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-04448
FILM NUMBER: 23992411
MAIL ADDRESS:
STREET 1: 1252 COOLIDGE AVE.
CITY: SAN JOSE
STATE: CA
ZIP: 95125
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BAXTER INTERNATIONAL INC
CENTRAL INDEX KEY: 0000010456
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 360781620
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE BAXTER PKWY
STREET 2: DF2-1W
CITY: DEERFIELD
STATE: IL
ZIP: 60015
BUSINESS PHONE: 8479482000
MAIL ADDRESS:
STREET 1: ONE BAXTER PARKWAY
STREET 2: DF2-1W
CITY: DEERFIELD
STATE: IL
ZIP: 60015
FORMER COMPANY:
FORMER CONFORMED NAME: BAXTER TRAVENOL LABORATORIES INC
DATE OF NAME CHANGE: 19880522
FORMER COMPANY:
FORMER CONFORMED NAME: BAXTER LABORATORIES INC
DATE OF NAME CHANGE: 19760608
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0407
4
2023-06-01
0000010456
BAXTER INTERNATIONAL INC
BAX
0001753950
Toth Christopher A.
ONE BAXTER PARKWAY
DEERFIELD
IL
60015
0
1
0
0
EVP, Group Pres, Kidney Care
0
Common Stock, $1 par value
2023-06-01
4
A
0
106358
0
A
106358
D
Mr. Toth received a grant of restricted stock units (RSUs)in connection with his appointment as EVP and Group President, Kidney Care. The RSUs are scheduled to vest in three equal annual installments beginning on June 3, 2024, the first anniversary of the grant date, subject to the terms and conditions set forth in the Baxter International Inc. 2021 Equity Plan. However, this award grant will vest in full if (i) by December 31, 2024, the proposed separation of the Kidney Care business (comprised of the Renal Care and Acute Therapies businesses) as a separately traded company (the "Business Transaction") does not occur; or (ii) in connection with the consummation of the Business Transaction, Mr. Toth is not appointed as Chief Executive Officer of the new company, Kidney Co.
/s/ Matthew Rice, as attorney in-fact for Christopher A. Toth
2023-06-05